nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—Abdominal pain upper—Capecitabine—esophageal cancer	0.00162	0.00249	CcSEcCtD
Duloxetine—Visual impairment—Cisplatin—esophageal cancer	0.0016	0.00247	CcSEcCtD
Duloxetine—Breast disorder—Capecitabine—esophageal cancer	0.0016	0.00246	CcSEcCtD
Duloxetine—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.0016	0.00245	CcSEcCtD
Duloxetine—Nasopharyngitis—Capecitabine—esophageal cancer	0.00158	0.00244	CcSEcCtD
Duloxetine—Gastritis—Capecitabine—esophageal cancer	0.00157	0.00241	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00156	0.0024	CcSEcCtD
Duloxetine—Muscular weakness—Capecitabine—esophageal cancer	0.00156	0.0024	CcSEcCtD
Duloxetine—Eye disorder—Cisplatin—esophageal cancer	0.00155	0.00239	CcSEcCtD
Duloxetine—Tinnitus—Cisplatin—esophageal cancer	0.00155	0.00239	CcSEcCtD
Duloxetine—Lymphadenopathy—Methotrexate—esophageal cancer	0.00155	0.00238	CcSEcCtD
Duloxetine—Flushing—Cisplatin—esophageal cancer	0.00154	0.00237	CcSEcCtD
Duloxetine—Cardiac disorder—Cisplatin—esophageal cancer	0.00154	0.00237	CcSEcCtD
Duloxetine—Dysphagia—Capecitabine—esophageal cancer	0.00153	0.00236	CcSEcCtD
Duloxetine—Influenza—Capecitabine—esophageal cancer	0.00153	0.00236	CcSEcCtD
Duloxetine—Diabetes mellitus—Methotrexate—esophageal cancer	0.00152	0.00233	CcSEcCtD
Duloxetine—Polyuria—Methotrexate—esophageal cancer	0.0015	0.00231	CcSEcCtD
Duloxetine—Immune system disorder—Cisplatin—esophageal cancer	0.0015	0.00231	CcSEcCtD
Duloxetine—Mediastinal disorder—Cisplatin—esophageal cancer	0.0015	0.00231	CcSEcCtD
Duloxetine—Sweating increased—Capecitabine—esophageal cancer	0.00149	0.00229	CcSEcCtD
Duloxetine—Arrhythmia—Cisplatin—esophageal cancer	0.00149	0.00229	CcSEcCtD
Duloxetine—Alopecia—Cisplatin—esophageal cancer	0.00147	0.00226	CcSEcCtD
Duloxetine—Abdominal discomfort—Capecitabine—esophageal cancer	0.00147	0.00226	CcSEcCtD
Duloxetine—Hepatic failure—Methotrexate—esophageal cancer	0.00147	0.00226	CcSEcCtD
Duloxetine—Malnutrition—Cisplatin—esophageal cancer	0.00145	0.00223	CcSEcCtD
Duloxetine—Erythema—Cisplatin—esophageal cancer	0.00145	0.00223	CcSEcCtD
Duloxetine—Dysuria—Capecitabine—esophageal cancer	0.00143	0.0022	CcSEcCtD
Duloxetine—Flatulence—Cisplatin—esophageal cancer	0.00143	0.00219	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00142	0.00219	CcSEcCtD
Duloxetine—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.0014	0.00215	CcSEcCtD
Duloxetine—Photosensitivity reaction—Capecitabine—esophageal cancer	0.0014	0.00215	CcSEcCtD
Duloxetine—Weight increased—Capecitabine—esophageal cancer	0.00139	0.00214	CcSEcCtD
Duloxetine—Visual disturbance—Methotrexate—esophageal cancer	0.00139	0.00214	CcSEcCtD
Duloxetine—Muscle spasms—Cisplatin—esophageal cancer	0.00139	0.00214	CcSEcCtD
Duloxetine—Weight decreased—Capecitabine—esophageal cancer	0.00139	0.00213	CcSEcCtD
Duloxetine—Hyperglycaemia—Capecitabine—esophageal cancer	0.00138	0.00213	CcSEcCtD
Duloxetine—Infestation NOS—Capecitabine—esophageal cancer	0.00137	0.0021	CcSEcCtD
Duloxetine—Infestation—Capecitabine—esophageal cancer	0.00137	0.0021	CcSEcCtD
Duloxetine—Vision blurred—Cisplatin—esophageal cancer	0.00136	0.0021	CcSEcCtD
Duloxetine—Tremor—Cisplatin—esophageal cancer	0.00136	0.00209	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00135	0.00208	CcSEcCtD
Duloxetine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00135	0.00207	CcSEcCtD
Duloxetine—Lethargy—Methotrexate—esophageal cancer	0.00135	0.00207	CcSEcCtD
Duloxetine—Ill-defined disorder—Cisplatin—esophageal cancer	0.00134	0.00207	CcSEcCtD
Duloxetine—Renal failure—Capecitabine—esophageal cancer	0.00134	0.00206	CcSEcCtD
Duloxetine—Myocardial infarction—Capecitabine—esophageal cancer	0.00134	0.00206	CcSEcCtD
Duloxetine—Anaemia—Cisplatin—esophageal cancer	0.00134	0.00206	CcSEcCtD
Duloxetine—Stomatitis—Capecitabine—esophageal cancer	0.00133	0.00205	CcSEcCtD
Duloxetine—Jaundice—Capecitabine—esophageal cancer	0.00133	0.00205	CcSEcCtD
Duloxetine—Conjunctivitis—Capecitabine—esophageal cancer	0.00133	0.00204	CcSEcCtD
Duloxetine—Urinary tract infection—Capecitabine—esophageal cancer	0.00133	0.00204	CcSEcCtD
Duloxetine—Osteoarthritis—Methotrexate—esophageal cancer	0.00132	0.00203	CcSEcCtD
Duloxetine—Malaise—Cisplatin—esophageal cancer	0.00131	0.00201	CcSEcCtD
Duloxetine—Leukopenia—Cisplatin—esophageal cancer	0.0013	0.00199	CcSEcCtD
Duloxetine—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00129	0.00199	CcSEcCtD
Duloxetine—Epistaxis—Capecitabine—esophageal cancer	0.00129	0.00198	CcSEcCtD
Duloxetine—Irritability—Methotrexate—esophageal cancer	0.00126	0.00194	CcSEcCtD
Duloxetine—Convulsion—Cisplatin—esophageal cancer	0.00125	0.00193	CcSEcCtD
Duloxetine—Mood swings—Methotrexate—esophageal cancer	0.00125	0.00192	CcSEcCtD
Duloxetine—Ataxia—Methotrexate—esophageal cancer	0.00124	0.00191	CcSEcCtD
Duloxetine—Myalgia—Cisplatin—esophageal cancer	0.00123	0.0019	CcSEcCtD
Duloxetine—Haemoglobin—Capecitabine—esophageal cancer	0.00123	0.0019	CcSEcCtD
Duloxetine—Anxiety—Cisplatin—esophageal cancer	0.00123	0.00189	CcSEcCtD
Duloxetine—Haemorrhage—Capecitabine—esophageal cancer	0.00123	0.00189	CcSEcCtD
Duloxetine—Hepatitis—Capecitabine—esophageal cancer	0.00123	0.00189	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00122	0.00188	CcSEcCtD
Duloxetine—Hypoaesthesia—Capecitabine—esophageal cancer	0.00122	0.00188	CcSEcCtD
Duloxetine—Liver function test abnormal—Methotrexate—esophageal cancer	0.00122	0.00187	CcSEcCtD
Duloxetine—Discomfort—Cisplatin—esophageal cancer	0.00122	0.00187	CcSEcCtD
Duloxetine—Pharyngitis—Capecitabine—esophageal cancer	0.00122	0.00187	CcSEcCtD
Duloxetine—Urinary tract disorder—Capecitabine—esophageal cancer	0.00121	0.00186	CcSEcCtD
Duloxetine—Oedema peripheral—Capecitabine—esophageal cancer	0.00121	0.00186	CcSEcCtD
Duloxetine—Connective tissue disorder—Capecitabine—esophageal cancer	0.0012	0.00185	CcSEcCtD
Duloxetine—Urethral disorder—Capecitabine—esophageal cancer	0.0012	0.00185	CcSEcCtD
Duloxetine—Breast disorder—Methotrexate—esophageal cancer	0.00119	0.00183	CcSEcCtD
Duloxetine—Oedema—Cisplatin—esophageal cancer	0.00118	0.00182	CcSEcCtD
Duloxetine—Anaphylactic shock—Cisplatin—esophageal cancer	0.00118	0.00182	CcSEcCtD
Duloxetine—Visual impairment—Capecitabine—esophageal cancer	0.00118	0.00182	CcSEcCtD
Duloxetine—Infection—Cisplatin—esophageal cancer	0.00117	0.00181	CcSEcCtD
Duloxetine—Erythema multiforme—Capecitabine—esophageal cancer	0.00116	0.00178	CcSEcCtD
Duloxetine—Nervous system disorder—Cisplatin—esophageal cancer	0.00116	0.00178	CcSEcCtD
Duloxetine—Thrombocytopenia—Cisplatin—esophageal cancer	0.00116	0.00178	CcSEcCtD
Duloxetine—Tachycardia—Cisplatin—esophageal cancer	0.00115	0.00177	CcSEcCtD
Duloxetine—Skin disorder—Cisplatin—esophageal cancer	0.00115	0.00177	CcSEcCtD
Duloxetine—Eye disorder—Capecitabine—esophageal cancer	0.00115	0.00176	CcSEcCtD
Duloxetine—Tinnitus—Capecitabine—esophageal cancer	0.00114	0.00176	CcSEcCtD
Duloxetine—Hyperhidrosis—Cisplatin—esophageal cancer	0.00114	0.00176	CcSEcCtD
Duloxetine—Flushing—Capecitabine—esophageal cancer	0.00114	0.00175	CcSEcCtD
Duloxetine—Cardiac disorder—Capecitabine—esophageal cancer	0.00114	0.00175	CcSEcCtD
Duloxetine—Anorexia—Cisplatin—esophageal cancer	0.00113	0.00173	CcSEcCtD
Duloxetine—Pancreatitis—Methotrexate—esophageal cancer	0.00112	0.00172	CcSEcCtD
Duloxetine—Angiopathy—Capecitabine—esophageal cancer	0.00111	0.00171	CcSEcCtD
Duloxetine—Immune system disorder—Capecitabine—esophageal cancer	0.00111	0.0017	CcSEcCtD
Duloxetine—Mediastinal disorder—Capecitabine—esophageal cancer	0.0011	0.0017	CcSEcCtD
Duloxetine—Chills—Capecitabine—esophageal cancer	0.0011	0.00169	CcSEcCtD
Duloxetine—Arrhythmia—Capecitabine—esophageal cancer	0.00109	0.00168	CcSEcCtD
Duloxetine—Abdominal discomfort—Methotrexate—esophageal cancer	0.00109	0.00168	CcSEcCtD
Duloxetine—Alopecia—Capecitabine—esophageal cancer	0.00108	0.00167	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00108	0.00166	CcSEcCtD
Duloxetine—Mental disorder—Capecitabine—esophageal cancer	0.00107	0.00165	CcSEcCtD
Duloxetine—Erythema—Capecitabine—esophageal cancer	0.00107	0.00164	CcSEcCtD
Duloxetine—Malnutrition—Capecitabine—esophageal cancer	0.00107	0.00164	CcSEcCtD
Duloxetine—Dysuria—Methotrexate—esophageal cancer	0.00107	0.00164	CcSEcCtD
Duloxetine—Paraesthesia—Cisplatin—esophageal cancer	0.00106	0.00163	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00106	0.00163	CcSEcCtD
Duloxetine—Flatulence—Capecitabine—esophageal cancer	0.00105	0.00162	CcSEcCtD
Duloxetine—Erectile dysfunction—Methotrexate—esophageal cancer	0.00105	0.00162	CcSEcCtD
Duloxetine—Dysgeusia—Capecitabine—esophageal cancer	0.00104	0.00161	CcSEcCtD
Duloxetine—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00104	0.0016	CcSEcCtD
Duloxetine—Back pain—Capecitabine—esophageal cancer	0.00103	0.00159	CcSEcCtD
Duloxetine—Decreased appetite—Cisplatin—esophageal cancer	0.00103	0.00158	CcSEcCtD
Duloxetine—Muscle spasms—Capecitabine—esophageal cancer	0.00103	0.00158	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00102	0.00157	CcSEcCtD
Duloxetine—Infestation NOS—Methotrexate—esophageal cancer	0.00102	0.00156	CcSEcCtD
Duloxetine—Infestation—Methotrexate—esophageal cancer	0.00102	0.00156	CcSEcCtD
Duloxetine—Pain—Cisplatin—esophageal cancer	0.00101	0.00155	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00101	0.00155	CcSEcCtD
Duloxetine—Vision blurred—Capecitabine—esophageal cancer	0.00101	0.00155	CcSEcCtD
Duloxetine—Tremor—Capecitabine—esophageal cancer	0.001	0.00154	CcSEcCtD
Duloxetine—Renal failure—Methotrexate—esophageal cancer	0.000999	0.00154	CcSEcCtD
Duloxetine—Stomatitis—Methotrexate—esophageal cancer	0.000991	0.00152	CcSEcCtD
Duloxetine—Ill-defined disorder—Capecitabine—esophageal cancer	0.00099	0.00152	CcSEcCtD
Duloxetine—Conjunctivitis—Methotrexate—esophageal cancer	0.000988	0.00152	CcSEcCtD
Duloxetine—Anaemia—Capecitabine—esophageal cancer	0.000986	0.00152	CcSEcCtD
Duloxetine—Feeling abnormal—Cisplatin—esophageal cancer	0.000973	0.0015	CcSEcCtD
Duloxetine—Malaise—Capecitabine—esophageal cancer	0.000962	0.00148	CcSEcCtD
Duloxetine—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000961	0.00148	CcSEcCtD
Duloxetine—Epistaxis—Methotrexate—esophageal cancer	0.000959	0.00147	CcSEcCtD
Duloxetine—Vertigo—Capecitabine—esophageal cancer	0.000959	0.00147	CcSEcCtD
Duloxetine—Syncope—Capecitabine—esophageal cancer	0.000957	0.00147	CcSEcCtD
Duloxetine—Leukopenia—Capecitabine—esophageal cancer	0.000955	0.00147	CcSEcCtD
Duloxetine—Palpitations—Capecitabine—esophageal cancer	0.000943	0.00145	CcSEcCtD
Duloxetine—Loss of consciousness—Capecitabine—esophageal cancer	0.000938	0.00144	CcSEcCtD
Duloxetine—Body temperature increased—Cisplatin—esophageal cancer	0.000934	0.00144	CcSEcCtD
Duloxetine—Cough—Capecitabine—esophageal cancer	0.000931	0.00143	CcSEcCtD
Duloxetine—Hypertension—Capecitabine—esophageal cancer	0.000921	0.00142	CcSEcCtD
Duloxetine—Haemoglobin—Methotrexate—esophageal cancer	0.000917	0.00141	CcSEcCtD
Duloxetine—Hepatitis—Methotrexate—esophageal cancer	0.000912	0.0014	CcSEcCtD
Duloxetine—Haemorrhage—Methotrexate—esophageal cancer	0.000912	0.0014	CcSEcCtD
Duloxetine—Chest pain—Capecitabine—esophageal cancer	0.000908	0.0014	CcSEcCtD
Duloxetine—Myalgia—Capecitabine—esophageal cancer	0.000908	0.0014	CcSEcCtD
Duloxetine—Arthralgia—Capecitabine—esophageal cancer	0.000908	0.0014	CcSEcCtD
Duloxetine—Pharyngitis—Methotrexate—esophageal cancer	0.000906	0.00139	CcSEcCtD
Duloxetine—Anxiety—Capecitabine—esophageal cancer	0.000905	0.00139	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000902	0.00139	CcSEcCtD
Duloxetine—Urinary tract disorder—Methotrexate—esophageal cancer	0.000901	0.00139	CcSEcCtD
Duloxetine—Discomfort—Capecitabine—esophageal cancer	0.000897	0.00138	CcSEcCtD
Duloxetine—Urethral disorder—Methotrexate—esophageal cancer	0.000894	0.00138	CcSEcCtD
Duloxetine—Dry mouth—Capecitabine—esophageal cancer	0.000888	0.00137	CcSEcCtD
Duloxetine—Visual impairment—Methotrexate—esophageal cancer	0.000879	0.00135	CcSEcCtD
Duloxetine—Confusional state—Capecitabine—esophageal cancer	0.000878	0.00135	CcSEcCtD
Duloxetine—Oedema—Capecitabine—esophageal cancer	0.000871	0.00134	CcSEcCtD
Duloxetine—Hypersensitivity—Cisplatin—esophageal cancer	0.00087	0.00134	CcSEcCtD
Duloxetine—Infection—Capecitabine—esophageal cancer	0.000865	0.00133	CcSEcCtD
Duloxetine—Erythema multiforme—Methotrexate—esophageal cancer	0.000863	0.00133	CcSEcCtD
Duloxetine—Shock—Capecitabine—esophageal cancer	0.000857	0.00132	CcSEcCtD
Duloxetine—Nervous system disorder—Capecitabine—esophageal cancer	0.000854	0.00131	CcSEcCtD
Duloxetine—Eye disorder—Methotrexate—esophageal cancer	0.000853	0.00131	CcSEcCtD
Duloxetine—Thrombocytopenia—Capecitabine—esophageal cancer	0.000853	0.00131	CcSEcCtD
Duloxetine—Tinnitus—Methotrexate—esophageal cancer	0.000851	0.00131	CcSEcCtD
Duloxetine—Tachycardia—Capecitabine—esophageal cancer	0.00085	0.00131	CcSEcCtD
Duloxetine—Asthenia—Cisplatin—esophageal cancer	0.000848	0.0013	CcSEcCtD
Duloxetine—Cardiac disorder—Methotrexate—esophageal cancer	0.000847	0.0013	CcSEcCtD
Duloxetine—Skin disorder—Capecitabine—esophageal cancer	0.000846	0.0013	CcSEcCtD
Duloxetine—Hyperhidrosis—Capecitabine—esophageal cancer	0.000842	0.0013	CcSEcCtD
Duloxetine—Anorexia—Capecitabine—esophageal cancer	0.00083	0.00128	CcSEcCtD
Duloxetine—Angiopathy—Methotrexate—esophageal cancer	0.000828	0.00127	CcSEcCtD
Duloxetine—Immune system disorder—Methotrexate—esophageal cancer	0.000824	0.00127	CcSEcCtD
Duloxetine—Mediastinal disorder—Methotrexate—esophageal cancer	0.000822	0.00127	CcSEcCtD
Duloxetine—Chills—Methotrexate—esophageal cancer	0.000819	0.00126	CcSEcCtD
Duloxetine—Diarrhoea—Cisplatin—esophageal cancer	0.000808	0.00124	CcSEcCtD
Duloxetine—Alopecia—Methotrexate—esophageal cancer	0.000806	0.00124	CcSEcCtD
Duloxetine—Mental disorder—Methotrexate—esophageal cancer	0.000799	0.00123	CcSEcCtD
Duloxetine—Malnutrition—Methotrexate—esophageal cancer	0.000794	0.00122	CcSEcCtD
Duloxetine—Erythema—Methotrexate—esophageal cancer	0.000794	0.00122	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000793	0.00122	CcSEcCtD
Duloxetine—Insomnia—Capecitabine—esophageal cancer	0.000788	0.00121	CcSEcCtD
Duloxetine—Paraesthesia—Capecitabine—esophageal cancer	0.000782	0.0012	CcSEcCtD
Duloxetine—Dysgeusia—Methotrexate—esophageal cancer	0.000778	0.0012	CcSEcCtD
Duloxetine—Back pain—Methotrexate—esophageal cancer	0.000768	0.00118	CcSEcCtD
Duloxetine—Dyspepsia—Capecitabine—esophageal cancer	0.000766	0.00118	CcSEcCtD
Duloxetine—Decreased appetite—Capecitabine—esophageal cancer	0.000757	0.00116	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000752	0.00116	CcSEcCtD
Duloxetine—Vomiting—Cisplatin—esophageal cancer	0.000751	0.00116	CcSEcCtD
Duloxetine—Fatigue—Capecitabine—esophageal cancer	0.000751	0.00116	CcSEcCtD
Duloxetine—Vision blurred—Methotrexate—esophageal cancer	0.000749	0.00115	CcSEcCtD
Duloxetine—Rash—Cisplatin—esophageal cancer	0.000745	0.00115	CcSEcCtD
Duloxetine—Constipation—Capecitabine—esophageal cancer	0.000745	0.00115	CcSEcCtD
Duloxetine—Pain—Capecitabine—esophageal cancer	0.000745	0.00115	CcSEcCtD
Duloxetine—Dermatitis—Cisplatin—esophageal cancer	0.000744	0.00114	CcSEcCtD
Duloxetine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000737	0.00113	CcSEcCtD
Duloxetine—Anaemia—Methotrexate—esophageal cancer	0.000734	0.00113	CcSEcCtD
Duloxetine—Feeling abnormal—Capecitabine—esophageal cancer	0.000718	0.0011	CcSEcCtD
Duloxetine—Malaise—Methotrexate—esophageal cancer	0.000716	0.0011	CcSEcCtD
Duloxetine—Vertigo—Methotrexate—esophageal cancer	0.000714	0.0011	CcSEcCtD
Duloxetine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000712	0.0011	CcSEcCtD
Duloxetine—Leukopenia—Methotrexate—esophageal cancer	0.000711	0.00109	CcSEcCtD
Duloxetine—Nausea—Cisplatin—esophageal cancer	0.000702	0.00108	CcSEcCtD
Duloxetine—Cough—Methotrexate—esophageal cancer	0.000693	0.00107	CcSEcCtD
Duloxetine—Urticaria—Capecitabine—esophageal cancer	0.000692	0.00106	CcSEcCtD
Duloxetine—Abdominal pain—Capecitabine—esophageal cancer	0.000688	0.00106	CcSEcCtD
Duloxetine—Body temperature increased—Capecitabine—esophageal cancer	0.000688	0.00106	CcSEcCtD
Duloxetine—Convulsion—Methotrexate—esophageal cancer	0.000688	0.00106	CcSEcCtD
Duloxetine—Chest pain—Methotrexate—esophageal cancer	0.000676	0.00104	CcSEcCtD
Duloxetine—Arthralgia—Methotrexate—esophageal cancer	0.000676	0.00104	CcSEcCtD
Duloxetine—Myalgia—Methotrexate—esophageal cancer	0.000676	0.00104	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000672	0.00103	CcSEcCtD
Duloxetine—Discomfort—Methotrexate—esophageal cancer	0.000668	0.00103	CcSEcCtD
Duloxetine—Confusional state—Methotrexate—esophageal cancer	0.000654	0.00101	CcSEcCtD
Duloxetine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000648	0.000997	CcSEcCtD
Duloxetine—Infection—Methotrexate—esophageal cancer	0.000644	0.000991	CcSEcCtD
Duloxetine—Hypersensitivity—Capecitabine—esophageal cancer	0.000642	0.000987	CcSEcCtD
Duloxetine—Nervous system disorder—Methotrexate—esophageal cancer	0.000636	0.000978	CcSEcCtD
Duloxetine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000635	0.000976	CcSEcCtD
Duloxetine—Skin disorder—Methotrexate—esophageal cancer	0.00063	0.000969	CcSEcCtD
Duloxetine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000627	0.000964	CcSEcCtD
Duloxetine—Asthenia—Capecitabine—esophageal cancer	0.000625	0.000961	CcSEcCtD
Duloxetine—Anorexia—Methotrexate—esophageal cancer	0.000618	0.000951	CcSEcCtD
Duloxetine—Pruritus—Capecitabine—esophageal cancer	0.000616	0.000948	CcSEcCtD
Duloxetine—Diarrhoea—Capecitabine—esophageal cancer	0.000596	0.000917	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000591	0.000909	CcSEcCtD
Duloxetine—Insomnia—Methotrexate—esophageal cancer	0.000586	0.000902	CcSEcCtD
Duloxetine—Paraesthesia—Methotrexate—esophageal cancer	0.000582	0.000896	CcSEcCtD
Duloxetine—Somnolence—Methotrexate—esophageal cancer	0.000576	0.000887	CcSEcCtD
Duloxetine—Dizziness—Capecitabine—esophageal cancer	0.000576	0.000886	CcSEcCtD
Duloxetine—Dyspepsia—Methotrexate—esophageal cancer	0.000571	0.000878	CcSEcCtD
Duloxetine—Decreased appetite—Methotrexate—esophageal cancer	0.000563	0.000867	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00056	0.000861	CcSEcCtD
Duloxetine—Fatigue—Methotrexate—esophageal cancer	0.000559	0.00086	CcSEcCtD
Duloxetine—Pain—Methotrexate—esophageal cancer	0.000554	0.000853	CcSEcCtD
Duloxetine—Vomiting—Capecitabine—esophageal cancer	0.000554	0.000852	CcSEcCtD
Duloxetine—Rash—Capecitabine—esophageal cancer	0.000549	0.000845	CcSEcCtD
Duloxetine—Dermatitis—Capecitabine—esophageal cancer	0.000549	0.000844	CcSEcCtD
Duloxetine—Headache—Capecitabine—esophageal cancer	0.000545	0.000839	CcSEcCtD
Duloxetine—Feeling abnormal—Methotrexate—esophageal cancer	0.000534	0.000822	CcSEcCtD
Duloxetine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00053	0.000816	CcSEcCtD
Duloxetine—Nausea—Capecitabine—esophageal cancer	0.000517	0.000796	CcSEcCtD
Duloxetine—Urticaria—Methotrexate—esophageal cancer	0.000515	0.000792	CcSEcCtD
Duloxetine—Body temperature increased—Methotrexate—esophageal cancer	0.000512	0.000788	CcSEcCtD
Duloxetine—Abdominal pain—Methotrexate—esophageal cancer	0.000512	0.000788	CcSEcCtD
Duloxetine—Hypersensitivity—Methotrexate—esophageal cancer	0.000478	0.000735	CcSEcCtD
Duloxetine—Asthenia—Methotrexate—esophageal cancer	0.000465	0.000716	CcSEcCtD
Duloxetine—Pruritus—Methotrexate—esophageal cancer	0.000459	0.000706	CcSEcCtD
Duloxetine—Diarrhoea—Methotrexate—esophageal cancer	0.000444	0.000682	CcSEcCtD
Duloxetine—Dizziness—Methotrexate—esophageal cancer	0.000429	0.00066	CcSEcCtD
Duloxetine—Vomiting—Methotrexate—esophageal cancer	0.000412	0.000634	CcSEcCtD
Duloxetine—Rash—Methotrexate—esophageal cancer	0.000409	0.000629	CcSEcCtD
Duloxetine—Dermatitis—Methotrexate—esophageal cancer	0.000408	0.000628	CcSEcCtD
Duloxetine—Headache—Methotrexate—esophageal cancer	0.000406	0.000625	CcSEcCtD
Duloxetine—Nausea—Methotrexate—esophageal cancer	0.000385	0.000592	CcSEcCtD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000218	0.000624	CbGpPWpGaD
Duloxetine—Protriptyline—ABCB1—esophageal cancer	0.000216	0.476	CrCbGaD
Duloxetine—HTR6—Signaling Pathways—CSNK1A1—esophageal cancer	0.000215	0.000615	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—ANXA1—esophageal cancer	0.000213	0.000609	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—GNG7—esophageal cancer	0.000211	0.000603	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKAP13—esophageal cancer	0.00021	0.000602	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000209	0.000599	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—SST—esophageal cancer	0.000207	0.000592	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—GHRL—esophageal cancer	0.000202	0.000577	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADCYAP1—esophageal cancer	0.000202	0.000577	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PDE4D—esophageal cancer	0.000201	0.000576	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PFN1—esophageal cancer	0.000201	0.000575	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HIF1A—esophageal cancer	0.000199	0.00057	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000198	0.000565	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KMT2D—esophageal cancer	0.000197	0.000562	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000193	0.000553	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PDE4D—esophageal cancer	0.000192	0.00055	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TP53—esophageal cancer	0.000192	0.000549	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—GNG7—esophageal cancer	0.000191	0.000547	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKAP13—esophageal cancer	0.000191	0.000546	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—KDR—esophageal cancer	0.00019	0.000545	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL2—esophageal cancer	0.000186	0.000531	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000186	0.000531	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—WWOX—esophageal cancer	0.000184	0.000528	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—GNG7—esophageal cancer	0.000183	0.000524	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ELMO1—esophageal cancer	0.000181	0.000516	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NOTCH1—esophageal cancer	0.000179	0.000513	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKAP13—esophageal cancer	0.000176	0.000505	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FKBP1A—esophageal cancer	0.000175	0.000502	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000175	0.000501	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PDE4D—esophageal cancer	0.000175	0.0005	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—ANXA1—esophageal cancer	0.000173	0.000494	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—WIF1—esophageal cancer	0.000171	0.000491	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL2—esophageal cancer	0.000169	0.000482	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—SST—esophageal cancer	0.000168	0.00048	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—GNG7—esophageal cancer	0.000166	0.000475	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—GHRL—esophageal cancer	0.000164	0.000468	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000163	0.000466	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CREBBP—esophageal cancer	0.000163	0.000465	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PDE4D—esophageal cancer	0.000161	0.000462	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL2—esophageal cancer	0.000161	0.000461	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—WWOX—esophageal cancer	0.00016	0.000458	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—EGFR—esophageal cancer	0.00016	0.000457	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.00016	0.000456	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CSNK1A1—esophageal cancer	0.000158	0.000453	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—ANXA1—esophageal cancer	0.000157	0.000448	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GNG7—esophageal cancer	0.000154	0.000439	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000153	0.000437	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—SST—esophageal cancer	0.000153	0.000436	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FKBP1A—esophageal cancer	0.000152	0.000436	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.00015	0.000429	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—ANXA1—esophageal cancer	0.00015	0.000429	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—WIF1—esophageal cancer	0.000149	0.000426	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—GHRL—esophageal cancer	0.000149	0.000425	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PFN1—esophageal cancer	0.000148	0.000423	CbGpPWpGaD
Duloxetine—Fluoxetine—ABCB1—esophageal cancer	0.000147	0.325	CrCbGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL2—esophageal cancer	0.000146	0.000419	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000146	0.000418	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000146	0.000418	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—SST—esophageal cancer	0.000146	0.000417	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NOS3—esophageal cancer	0.000146	0.000417	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000146	0.000417	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—XIAP—esophageal cancer	0.000144	0.000412	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—GHRL—esophageal cancer	0.000142	0.000406	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.00014	0.0004	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000139	0.000398	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—PIK3CA—esophageal cancer	0.000139	0.000397	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CSNK1A1—esophageal cancer	0.000137	0.000393	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ERBB2—esophageal cancer	0.000136	0.00039	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—ANXA1—esophageal cancer	0.000136	0.000389	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CTNNA1—esophageal cancer	0.000136	0.000389	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL2—esophageal cancer	0.000135	0.000387	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ELMO1—esophageal cancer	0.000133	0.00038	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—SST—esophageal cancer	0.000132	0.000379	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.00013	0.000373	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.00013	0.000373	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKAP13—esophageal cancer	0.00013	0.000372	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—GHRL—esophageal cancer	0.000129	0.000369	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PFN1—esophageal cancer	0.000129	0.000368	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000126	0.000362	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PSME1—esophageal cancer	0.000126	0.000361	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PSME2—esophageal cancer	0.000126	0.000361	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ANXA1—esophageal cancer	0.000126	0.00036	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CA1—esophageal cancer	0.000124	0.000355	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000124	0.000355	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000124	0.000355	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—BLVRB—esophageal cancer	0.000124	0.000354	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC52A3—esophageal cancer	0.000124	0.000354	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SST—esophageal cancer	0.000122	0.00035	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCND1—esophageal cancer	0.00012	0.000344	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HIST1H2BM—esophageal cancer	0.00012	0.000343	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GHRL—esophageal cancer	0.000119	0.000341	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOTCH3—esophageal cancer	0.000119	0.000341	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PDE4D—esophageal cancer	0.000119	0.00034	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FBXW7—esophageal cancer	0.000117	0.000335	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CDKN1A—esophageal cancer	0.000116	0.000333	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ELMO1—esophageal cancer	0.000115	0.00033	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CA2—esophageal cancer	0.000114	0.000325	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000113	0.000324	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GNG7—esophageal cancer	0.000113	0.000323	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKAP13—esophageal cancer	0.000113	0.000323	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EP300—esophageal cancer	0.000111	0.000317	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000111	0.000316	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOTCH2—esophageal cancer	0.000107	0.000306	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—XIAP—esophageal cancer	0.000106	0.000303	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000106	0.000302	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000106	0.000302	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CA1—esophageal cancer	0.000105	0.000301	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC10A2—esophageal cancer	0.000105	0.000301	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000104	0.000298	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PDE4D—esophageal cancer	0.000103	0.000295	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CTNNA1—esophageal cancer	0.0001	0.000287	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL2—esophageal cancer	9.96e-05	0.000285	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GNG7—esophageal cancer	9.82e-05	0.000281	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MYC—esophageal cancer	9.65e-05	0.000276	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CA2—esophageal cancer	9.62e-05	0.000275	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFBR2—esophageal cancer	9.49e-05	0.000271	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EGFR—esophageal cancer	9.44e-05	0.00027	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	9.4e-05	0.000269	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PSME2—esophageal cancer	9.31e-05	0.000266	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PSME1—esophageal cancer	9.31e-05	0.000266	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ANXA1—esophageal cancer	9.26e-05	0.000265	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ADH1B—esophageal cancer	9.26e-05	0.000265	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—XIAP—esophageal cancer	9.2e-05	0.000263	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SST—esophageal cancer	9.01e-05	0.000258	CbGpPWpGaD
Duloxetine—Propranolol—ABCB1—esophageal cancer	8.98e-05	0.198	CrCbGaD
Duloxetine—HTR6—Signaling Pathways—SMAD4—esophageal cancer	8.98e-05	0.000257	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLCE1—esophageal cancer	8.94e-05	0.000256	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ADH7—esophageal cancer	8.94e-05	0.000256	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TYMP—esophageal cancer	8.85e-05	0.000253	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	8.84e-05	0.000253	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GHRL—esophageal cancer	8.78e-05	0.000251	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOTCH3—esophageal cancer	8.78e-05	0.000251	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CTNNA1—esophageal cancer	8.7e-05	0.000249	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL2—esophageal cancer	8.65e-05	0.000247	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FBXW7—esophageal cancer	8.64e-05	0.000247	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP26A1—esophageal cancer	8.61e-05	0.000246	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALOX15—esophageal cancer	8.39e-05	0.00024	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PIK3CA—esophageal cancer	8.2e-05	0.000234	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PSME2—esophageal cancer	8.08e-05	0.000231	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PSME1—esophageal cancer	8.08e-05	0.000231	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ANXA1—esophageal cancer	8.04e-05	0.00023	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTO1—esophageal cancer	8e-05	0.000229	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TPI1—esophageal cancer	8e-05	0.000229	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—esophageal cancer	7.93e-05	0.000227	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOTCH2—esophageal cancer	7.87e-05	0.000225	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ADH1B—esophageal cancer	7.84e-05	0.000224	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SST—esophageal cancer	7.82e-05	0.000224	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALDOB—esophageal cancer	7.67e-05	0.000219	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH3—esophageal cancer	7.62e-05	0.000218	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GHRL—esophageal cancer	7.62e-05	0.000218	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FBXW7—esophageal cancer	7.5e-05	0.000215	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TYMP—esophageal cancer	7.5e-05	0.000214	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GAPDH—esophageal cancer	7.38e-05	0.000211	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HIF1A—esophageal cancer	7.35e-05	0.00021	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CRABP1—esophageal cancer	7.32e-05	0.000209	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP26A1—esophageal cancer	7.29e-05	0.000209	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALOX15—esophageal cancer	7.11e-05	0.000203	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KDR—esophageal cancer	7.03e-05	0.000201	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFBR2—esophageal cancer	6.99e-05	0.0002	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GNG7—esophageal cancer	6.96e-05	0.000199	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH2—esophageal cancer	6.84e-05	0.000196	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TPI1—esophageal cancer	6.78e-05	0.000194	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTO1—esophageal cancer	6.78e-05	0.000194	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOTCH1—esophageal cancer	6.62e-05	0.000189	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SMAD4—esophageal cancer	6.61e-05	0.000189	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALDH2—esophageal cancer	6.52e-05	0.000187	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALDOB—esophageal cancer	6.5e-05	0.000186	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GAPDH—esophageal cancer	6.26e-05	0.000179	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTT1—esophageal cancer	6.2e-05	0.000177	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CRABP1—esophageal cancer	6.2e-05	0.000177	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	6.13e-05	0.000175	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFBR2—esophageal cancer	6.07e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CREBBP—esophageal cancer	6e-05	0.000172	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GNG7—esophageal cancer	5.9e-05	0.000169	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EGFR—esophageal cancer	5.9e-05	0.000169	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS1—esophageal cancer	5.81e-05	0.000166	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ENO1—esophageal cancer	5.81e-05	0.000166	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SMAD4—esophageal cancer	5.74e-05	0.000164	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PSME1—esophageal cancer	5.73e-05	0.000164	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PSME2—esophageal cancer	5.73e-05	0.000164	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CA—esophageal cancer	5.64e-05	0.000161	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALDH2—esophageal cancer	5.53e-05	0.000158	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HIF1A—esophageal cancer	5.41e-05	0.000155	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOS3—esophageal cancer	5.37e-05	0.000154	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTT1—esophageal cancer	5.26e-05	0.00015	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2A6—esophageal cancer	5.2e-05	0.000149	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	5.18e-05	0.000148	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KDR—esophageal cancer	5.17e-05	0.000148	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CA—esophageal cancer	5.12e-05	0.000146	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ERBB2—esophageal cancer	5.03e-05	0.000144	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	4.94e-05	0.000141	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS1—esophageal cancer	4.93e-05	0.000141	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ENO1—esophageal cancer	4.93e-05	0.000141	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOTCH1—esophageal cancer	4.87e-05	0.000139	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PSME1—esophageal cancer	4.85e-05	0.000139	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PSME2—esophageal cancer	4.85e-05	0.000139	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	4.7e-05	0.000134	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	4.65e-05	0.000133	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KDR—esophageal cancer	4.49e-05	0.000129	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—esophageal cancer	4.44e-05	0.000127	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	4.42e-05	0.000126	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	4.34e-05	0.000124	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1A—esophageal cancer	4.3e-05	0.000123	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMOX1—esophageal cancer	4.24e-05	0.000121	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.24e-05	0.000121	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	4.23e-05	0.000121	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	4.19e-05	0.00012	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	4.15e-05	0.000119	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EP300—esophageal cancer	4.09e-05	0.000117	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCB1—esophageal cancer	4.07e-05	0.000116	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOS3—esophageal cancer	3.96e-05	0.000113	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	3.94e-05	0.000113	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	3.84e-05	0.00011	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	3.77e-05	0.000108	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	3.77e-05	0.000108	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	3.7e-05	0.000106	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	3.6e-05	0.000103	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMOX1—esophageal cancer	3.59e-05	0.000103	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—esophageal cancer	3.56e-05	0.000102	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.52e-05	0.000101	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—esophageal cancer	3.48e-05	9.96e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCB1—esophageal cancer	3.45e-05	9.86e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOS3—esophageal cancer	3.44e-05	9.83e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	3.27e-05	9.36e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—esophageal cancer	3.27e-05	9.35e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	3.21e-05	9.19e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	3.16e-05	9.05e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CA—esophageal cancer	3.02e-05	8.65e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EP300—esophageal cancer	3.01e-05	8.61e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—esophageal cancer	2.92e-05	8.37e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—esophageal cancer	2.84e-05	8.12e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	2.75e-05	7.86e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CREBBP—esophageal cancer	2.72e-05	7.78e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—esophageal cancer	2.62e-05	7.5e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EP300—esophageal cancer	2.61e-05	7.48e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.61e-05	7.46e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—esophageal cancer	2.57e-05	7.34e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NOS3—esophageal cancer	2.44e-05	6.97e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CREBBP—esophageal cancer	2.3e-05	6.59e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—esophageal cancer	2.28e-05	6.51e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—esophageal cancer	2.23e-05	6.37e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—esophageal cancer	2.23e-05	6.37e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	2.23e-05	6.37e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—esophageal cancer	2.15e-05	6.16e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NOS3—esophageal cancer	2.06e-05	5.9e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	1.93e-05	5.53e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—esophageal cancer	1.89e-05	5.4e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—esophageal cancer	1.87e-05	5.35e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—EP300—esophageal cancer	1.85e-05	5.3e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—EP300—esophageal cancer	1.57e-05	4.49e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.37e-05	3.92e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.16e-05	3.32e-05	CbGpPWpGaD
